Table 2.
Characteristics of patients in the first stage of path A (stage 8) versus path B (stage 9)
| Measurement | Path A Median (IQR) |
Path B Median (IQR) |
P-value |
|---|---|---|---|
| Hippocampal volume (%TIV) | 0.3552 (0.3500–0.3660) | 0.4192 (0.4084–0.4275) | .117 |
| FDG-PET SUVR | 1.17 (1.16–1.19) | 1.19 (1.18–1.20) | .300 |
| CSF Aβ42 (pg/mL) | 159.0 (150.0–170.0) | 129.0 (128.0–132.0) | .035 |
| CSF t-tau (pg/mL) | 70.3 (64.8–76.5) | 121.0 (114.0–127.0) | .025 |
| CSF p-tau (pg/mL) | 29.6 (25.6–33.1) | 50.8 (47.5–53.0) | .026 |
| Amyloid PET SUVR | 1.26 (1.15–1.31) | 1.40 (1.38–1.43) | .030 |
| ADAS-Cog | 18.0 (17.7–18.7) | 21.0 (20.0–21.7) | .050 |
| TRAILS-B | 112.0 (105.0–119.0) | 104.0 (98.5–111.5) | .332 |
| FAQ | 3 (3–4) | 5 (4–6) | .224 |
| RAVLT | 33 (32–34) | 30 (29–31) | .106 |
| MMSE | 27 (27–27) | 26 (26–26) | .107 |
| CDR | 2.5 (2.0–2.5) | 2.5 (2.5–3.0) | .324 |
| Age (years) | 80.8 (79.9–81.6) | 72.4 (71.6–73.3) | .063 |
Abbreviations: SUVR, standard uptake value ratio; FDG, fludeoxyglucose F-18; PET, positron emission tomography; TIV, total intracranial volume; ADAS-Cog, Alzheimer's Disease Assessment Scale Cognitive Subscale; FAQ, Family Activities Questionnaire; RAVLT, Rey Auditory Verbal Learning Test; MMSE, Mini–Mental State Examination; CDR, clinical dementia rating; IQR, interquartile range.
NOTE. Based on these measurements, predictions about the trajectory of a patient's disease through either path A or B can be made.